Richmond Pharmacology welcomes you to attend the ACCP 40th Annual Meeting, taking place 11th to 13th Sept, 2011

Posted:

September 2011

Richmond Pharmacology welcomes you to attend the ACCP 40th Annual Meeting, taking place 11th to 13th Sept, 2011 at the Crowne Plaza Chicago O'Hare Hotel. This years meeting promises to be an exciting event that will hosting a series of excellent workshops and symposia on current, relevant topics related to improving the optimal development and use of therapeutics, with a specific focus on clinical pharmacology.Richmond Pharmacologys CEO and co-founder Dr Jorg Taubel is due to present on Monday 12th September from 18h00 to 20h00, covering the following topics of discussion:

Alternative Methods for The Confirmation Of Assay Sensitivity In Thorough QT Studies
The Use of Non-invasive Blood Pressure Recording By Photoplethysmography In Early Phase Clinical Trial Studies

Furthermore, Richmond Pharmacology will be exhibiting at the meeting, if you plan to attend we welcome you to come see us at booth number 3 to learn more about our service offering and how our specialist expertise can enhance your next clinical study. If you would like to arrange a face to face meeting with Dr Taubel, please contact a member of our business development team to arrange a time at your convenience.

Back to news

More about us Adaptive Phase I, II & III Bridging Studies TQT Studies Patient Recruitment

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Latest Publications

View our latest peer-reviewed publications from a selection of our clinical trials.

Latest Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020

Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.

View event

COVID-19 – External Monitoring Guidelines

July 1, 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

First transdermal patch to treat schizophrenia hits market

March 18, 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Statement: COVID-19

March 23, 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.